We Think Mayne Pharma Group Limited's (ASX:MYX) CEO Compensation Package Needs To Be Put Under A Microscope
The results at Mayne Pharma Group Limited ( ASX:MYX ) have been quite disappointing recently and CEO Scott Richards...
Has the Australian Pharma Industry valuation changed over the past few years?
|Sun, 28 Nov 2021||AU$4.6b||AU$758.4m||-AU$450,516,414.00||23.3x|
|Tue, 26 Oct 2021||AU$4.8b||AU$753.7m||-AU$449,109,205.00||24.4x|
|Thu, 23 Sep 2021||AU$4.7b||AU$753.9m||-AU$445,060,581.00||22.1x|
|Sat, 21 Aug 2021||AU$4.1b||AU$752.8m||-AU$442,004,016.00||21.1x|
|Sat, 05 Jun 2021||AU$4.5b||AU$758.8m||-AU$452,149,714.00||12.7x|
|Tue, 09 Mar 2021||AU$4.8b||AU$759.6m||-AU$478,696,362.00||71.8x|
|Mon, 30 Nov 2020||AU$4.2b||AU$761.5m||-AU$402,127,165.00||26.6x|
|Thu, 03 Sep 2020||AU$4.0b||AU$773.8m||-AU$314,501,632.00||43.1x|
|Sun, 07 Jun 2020||AU$4.1b||AU$767.4m||-AU$405,897,729.00||47.9x|
|Sat, 29 Feb 2020||AU$3.6b||AU$773.8m||-AU$489,584,699.00||22.9x|
|Tue, 03 Dec 2019||AU$4.3b||AU$792.3m||-AU$452,512,211.00||25.3x|
|Fri, 06 Sep 2019||AU$4.3b||AU$809.9m||-AU$422,273,520.00||37.5x|
|Mon, 10 Jun 2019||AU$4.1b||AU$784.7m||-AU$259,069,235.00||25.5x|
|Sun, 03 Mar 2019||AU$3.3b||AU$783.5m||-AU$86,418,712.00||25.9x|
|Wed, 05 Dec 2018||AU$4.2b||AU$752.5m||-AU$192,213,841.00||37.5x|
Current Industry PE: Investors are more pessimistic on the industry, considering it's trading at a PE ratio of 23.3x which is lower than its 3-year average PE of 31.3x. It appears they believe that earnings will not grow as fast as they have historically.
Past Earnings Growth: The earnings for companies in the Pharmaceuticals industry have deteriorated over the last three years, while revenues have remained mostly flat. This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.
Which industries have driven the changes within the Australian Pharma industry?
Industry PE: Investors are most optimistic about the Pharma industry even though it's trading below its 3-year average PE ratio of 31.3x. This is likely because analysts are expecting annual earnings growth of 67%, which is higher than its past year's earnings growth of 5.6% per year.
Forecasted Growth: Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 67% over the next 5 years. This is better than it's past earnings growth rate of 5.6% per year.
Which companies have driven the market over the last 7 days?
Little Green Pharma
Mayne Pharma Group
AusCann Group Holdings